CN104349793B - 寡核苷酸螯合物‑多肽组合物和方法 - Google Patents

寡核苷酸螯合物‑多肽组合物和方法 Download PDF

Info

Publication number
CN104349793B
CN104349793B CN201380026009.3A CN201380026009A CN104349793B CN 104349793 B CN104349793 B CN 104349793B CN 201380026009 A CN201380026009 A CN 201380026009A CN 104349793 B CN104349793 B CN 104349793B
Authority
CN
China
Prior art keywords
pharmaceutical composition
chelates
seq
rep
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380026009.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104349793A (zh
Inventor
米歇尔·巴齐内
安德鲁·瓦利恩特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104349793(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CN104349793A publication Critical patent/CN104349793A/zh
Application granted granted Critical
Publication of CN104349793B publication Critical patent/CN104349793B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CN201380026009.3A 2012-05-18 2013-05-17 寡核苷酸螯合物‑多肽组合物和方法 Active CN104349793B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US61/648,711 2012-05-18
US201261695035P 2012-08-30 2012-08-30
US61/695,035 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (2)

Publication Number Publication Date
CN104349793A CN104349793A (zh) 2015-02-11
CN104349793B true CN104349793B (zh) 2017-11-10

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380026009.3A Active CN104349793B (zh) 2012-05-18 2013-05-17 寡核苷酸螯合物‑多肽组合物和方法

Country Status (34)

Country Link
US (1) US9492506B2 (https=)
EP (1) EP2849798B1 (https=)
JP (1) JP2015517504A (https=)
KR (1) KR102068109B1 (https=)
CN (1) CN104349793B (https=)
AU (1) AU2013262416B2 (https=)
BR (1) BR112014028654A2 (https=)
CA (1) CA2873529C (https=)
CL (1) CL2014003134A1 (https=)
CO (1) CO7131387A2 (https=)
CR (1) CR20140527A (https=)
CY (1) CY1124345T1 (https=)
DK (1) DK2849798T3 (https=)
DO (1) DOP2014000264A (https=)
EA (1) EA035967B1 (https=)
EC (1) ECSP14027694A (https=)
ES (1) ES2873844T3 (https=)
HR (1) HRP20210840T1 (https=)
HU (1) HUE054875T2 (https=)
IL (1) IL235548B (https=)
LT (1) LT2849798T (https=)
MX (1) MX346239B (https=)
MY (1) MY168778A (https=)
NZ (1) NZ703095A (https=)
PH (1) PH12014502551B1 (https=)
PL (1) PL2849798T3 (https=)
PT (1) PT2849798T (https=)
RS (1) RS62030B1 (https=)
SG (1) SG11201407599SA (https=)
SI (1) SI2849798T1 (https=)
SM (1) SMT202100319T1 (https=)
TW (1) TWI635864B (https=)
WO (1) WO2013170386A1 (https=)
ZA (1) ZA201408674B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
SG11201501255PA (en) * 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
CN106659730A (zh) 2014-07-10 2017-05-10 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2012021985A1 (en) * 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
BR0314236A (pt) * 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
CA2516552A1 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
JP2007509950A (ja) * 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
CA2584207A1 (en) * 2004-10-19 2006-04-27 Replicor, Inc. Antiviral oligonucleotides
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
US20090215873A1 (en) 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
BR112012008865A2 (pt) * 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2012021985A1 (en) * 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes

Also Published As

Publication number Publication date
AU2013262416B2 (en) 2017-05-11
EA035967B1 (ru) 2020-09-07
HUE054875T2 (hu) 2021-10-28
HRP20210840T1 (hr) 2021-08-06
CA2873529A1 (en) 2013-11-21
KR20150013309A (ko) 2015-02-04
EP2849798B1 (en) 2021-04-07
DK2849798T3 (da) 2021-05-31
ZA201408674B (en) 2016-01-27
PH12014502551B1 (en) 2019-10-11
US20130309201A1 (en) 2013-11-21
MY168778A (en) 2018-12-04
IL235548A0 (en) 2015-01-29
MX2014014021A (es) 2015-02-10
LT2849798T (lt) 2021-08-10
TW201408308A (zh) 2014-03-01
CA2873529C (en) 2020-08-18
MX346239B (es) 2017-03-13
WO2013170386A1 (en) 2013-11-21
EP2849798A1 (en) 2015-03-25
TWI635864B (zh) 2018-09-21
SG11201407599SA (en) 2014-12-30
EA201401278A1 (ru) 2015-04-30
BR112014028654A2 (pt) 2017-10-10
CR20140527A (es) 2014-12-15
EP2849798A4 (en) 2016-03-09
CN104349793A (zh) 2015-02-11
IL235548B (en) 2019-07-31
JP2015517504A (ja) 2015-06-22
PL2849798T3 (pl) 2021-10-18
CY1124345T1 (el) 2022-07-22
ECSP14027694A (es) 2015-12-31
DOP2014000264A (es) 2015-01-31
RS62030B1 (sr) 2021-07-30
US9492506B2 (en) 2016-11-15
PH12014502551A1 (en) 2015-01-21
SMT202100319T1 (it) 2021-09-14
CL2014003134A1 (es) 2015-02-13
ES2873844T3 (es) 2021-11-04
PT2849798T (pt) 2021-05-18
KR102068109B1 (ko) 2020-01-21
SI2849798T1 (sl) 2021-08-31
AU2013262416A1 (en) 2014-12-18
HK1204279A1 (en) 2015-11-13
CO7131387A2 (es) 2014-12-01
NZ703095A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
CN104349793B (zh) 寡核苷酸螯合物‑多肽组合物和方法
AU2011329668B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20190062749A1 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
CN103768086B (zh) 寡核苷酸螯合物的用途
CN104379152B (zh) 寡核苷酸螯合物方法
US20110009477A1 (en) Oligonucleotide-based compounds as inhibitors of toll-like receptors
CN116367841A (zh) 用于治疗病毒性疾病的含有核苷的siRNA
JP2024541559A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）タンパク質の発現を阻害するための組成物および方法
EP4183879A1 (en) Double-stranded oligonucleotide and composition for treating covid-19 containing same
HK1204279B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
HK1206259B (zh) 寡核苷酸螯合物方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204279

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1204279

Country of ref document: HK